<?xml version="1.0" encoding="UTF-8"?>
<p>Currently five vaccine candidates are in clinical stages of development [
 <xref rid="pntd.0006847.ref020" ref-type="bibr">20</xref>]. Only one vaccine has completed two Phase III trials and it is being licensed for introduction in several countries [
 <xref rid="pntd.0006847.ref021" ref-type="bibr">21</xref>â€“
 <xref rid="pntd.0006847.ref023" ref-type="bibr">23</xref>]. This vaccine has an estimated efficacy of 64.7% and 56.5% in the Latin American and Southeast Asian trials, respectively and the efficacy was significantly higher in participants with pre-existing dengue neutralizing antibodies compared to those who were seronegative [
 <xref rid="pntd.0006847.ref021" ref-type="bibr">21</xref>, 
 <xref rid="pntd.0006847.ref022" ref-type="bibr">22</xref>, 
 <xref rid="pntd.0006847.ref024" ref-type="bibr">24</xref>].
</p>
